Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity

Claudio Trapella, Rebecca Voltan, Elisabetta Melloni, Veronica Tisato, Claudio Celeghini, Sara Bianco, Anna Fantinati, Severo Salvadori, Remo Guerrini, Paola Secchiero, Giorgio Zauli

Research output: Contribution to journalArticle

Abstract

The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.

Original languageEnglish
Pages (from-to)147-156
Number of pages10
JournalJournal of Medicinal Chemistry
Volume59
Issue number1
DOIs
Publication statusPublished - Jan 14 2016

Fingerprint

Mitochondria
Glycolysis
Biological Availability
Amines
Phosphotransferases
Neoplasms
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. / Trapella, Claudio; Voltan, Rebecca; Melloni, Elisabetta; Tisato, Veronica; Celeghini, Claudio; Bianco, Sara; Fantinati, Anna; Salvadori, Severo; Guerrini, Remo; Secchiero, Paola; Zauli, Giorgio.

In: Journal of Medicinal Chemistry, Vol. 59, No. 1, 14.01.2016, p. 147-156.

Research output: Contribution to journalArticle

Trapella, C, Voltan, R, Melloni, E, Tisato, V, Celeghini, C, Bianco, S, Fantinati, A, Salvadori, S, Guerrini, R, Secchiero, P & Zauli, G 2016, 'Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity', Journal of Medicinal Chemistry, vol. 59, no. 1, pp. 147-156. https://doi.org/10.1021/acs.jmedchem.5b01165
Trapella, Claudio ; Voltan, Rebecca ; Melloni, Elisabetta ; Tisato, Veronica ; Celeghini, Claudio ; Bianco, Sara ; Fantinati, Anna ; Salvadori, Severo ; Guerrini, Remo ; Secchiero, Paola ; Zauli, Giorgio. / Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 1. pp. 147-156.
@article{41ddc8d88c484cbebd2e99f1b4b241c0,
title = "Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity",
abstract = "The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.",
author = "Claudio Trapella and Rebecca Voltan and Elisabetta Melloni and Veronica Tisato and Claudio Celeghini and Sara Bianco and Anna Fantinati and Severo Salvadori and Remo Guerrini and Paola Secchiero and Giorgio Zauli",
year = "2016",
month = "1",
day = "14",
doi = "10.1021/acs.jmedchem.5b01165",
language = "English",
volume = "59",
pages = "147--156",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity

AU - Trapella, Claudio

AU - Voltan, Rebecca

AU - Melloni, Elisabetta

AU - Tisato, Veronica

AU - Celeghini, Claudio

AU - Bianco, Sara

AU - Fantinati, Anna

AU - Salvadori, Severo

AU - Guerrini, Remo

AU - Secchiero, Paola

AU - Zauli, Giorgio

PY - 2016/1/14

Y1 - 2016/1/14

N2 - The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.

AB - The mitochondrial kinase inhibitor dichloroacetate (DCA) has recently received attention in oncology due to its ability to target glycolysis. However, DCA molecule exhibits poor bioavailability and cellular uptake with limited ability to reach its target mitochondria. To overcome these biases, we have synthesized novel DCA-loaded compounds. The selection of the most promising therapeutic molecule was evaluated by combining in vitro assays, to test the antitumoral potential on leukemic cells, and a preliminary characterization of the molecule stability in vivo, in mice. Among the newly synthesized compounds, we have selected the multiple DCA-loaded compound 10, characterized by a tertiary amine scaffold, because it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in vivo stability. On the basis of these results, we believe that compound 10 should be considered for further preclinical evaluations for the treatment of cancers and/or other diseases characterized by altered metabolic origin.

UR - http://www.scopus.com/inward/record.url?scp=84955156510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955156510&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b01165

DO - 10.1021/acs.jmedchem.5b01165

M3 - Article

C2 - 26653539

AN - SCOPUS:84955156510

VL - 59

SP - 147

EP - 156

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -